Role of gefitinib (G) in heavily pretreated non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Tamburini, E.
Tassinari, D.
Pasquini, E.
Papi, M.
Possenti, C.
Drudi, F.
Castellani, C.
Santelmo, C.
Carloni, F.
Ravaioli, A.
机构：
[1] Dept Oncol, Rimini, Italy
[2] Dept Oncol, Cattolica, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19102
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Safety of gefitinib in non-small cell lung cancer treatment
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 993 - 1000
  • [42] Genotyping Non-Small Cell Lung Cancer (NSCLC)
    Delia Campos-Parra, Alma
    Cruz-Rico, Graciela
    Arrieta, Oscar
    GACETA MEXICANA DE ONCOLOGIA, 2012, 11 (01): : 35 - 44
  • [43] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
  • [44] Eicosanoids in non-small cell lung cancer (NSCLC)
    Johnson, D. H.
    Horn, L.
    Zhao, Z.
    Milne, G.
    Morrow, J.
    Sandler, A.
    Shyr, Y.
    Carbone, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
    Christian Manegold
    Petr Zatloukal
    Kurt Krejcy
    Johannes Blatter
    Investigational New Drugs, 2000, 18 : 29 - 42
  • [46] BRCAness in non-small cell lung cancer (NSCLC).
    Waqar, Saiama Naheed
    Devarakonda, Siddhartha H. K.
    Michel, Loren S.
    Maggi, Leonard B.
    Watson, Mark
    Guebert, Kalin
    Carpenter, Danielle
    Sleckman, Barry P.
    Govindan, Ramaswamy
    Morgensztern, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Phase I summary of the HB0025 efficacy and safety to the heavily pretreated non-small cell lung cancer (NSCLC) population.
    Meng, Yanchun
    Du, Yiqun
    Liu, Xiaojun
    Mu, Yuxin
    Sun, Meili
    Wen, Qing
    Liu, Ning
    Chen, Hua
    Sun, Yuping
    Dang, Qi
    Ni, Shuqin
    Wang, Zhen
    Li, Xiumin
    Liu, Lian
    Wang, Benjie
    Zhang, Jian
    Yang, Yang
    Zheng, Yang, Sr.
    Yang, Si
    Wang, Junning
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Gemcitabine in non-small cell lung cancer (NSCLC)
    Manegold, C
    Zatloukal, P
    Krejcy, K
    Blatter, J
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) : 29 - 42
  • [49] Optimum timing of gefitinib therapy in metastatic non-small cell lung cancer (NSCLC) patients.
    Ayllon, J
    Plazanet, V
    Guillevin, EF
    Banu, E
    Bonan, B
    Oudard, S
    Barthes, FP
    Theou, N
    Sors, H
    Andrieu, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 700S - 700S
  • [50] Clinical factors affecting the late resistance to gefitinib in patients with non-small cell lung cancer (NSCLC).
    Segawa, Y.
    Hotta, K.
    Umemura, S.
    Fujiwara, Y.
    Shinkai, T.
    Ueoka, H.
    Takigawa, N.
    Tabata, M.
    Kiura, K.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 411S - 411S
12345